email : Webview : EUpdate January 2017

2016: A YEAR OF "FIRSTS" FOR NETRF

Looking back on 2016, NETRF took giant steps to transform the approach to neuroendocrine tumor research. We are proud of our efforts to ACCELERATE, INNOVATE, COLLABORATE, and EDUCATE. Thank you to all our donors, researchers, and volunteers, without whom we could not have achieved this progress.

NETRF has accelerated our research funding, thanks to the generous support of the Margie and Robert E. Petersen Foundation. We developed the new Accelerator Grants program—looking for the best ideas from the best research teams. READ MORE

MICHAEL GERMAN NAMED NETRF PETERSEN INVESTIGATOR

Project Results Will Provide Insight Into Mechanisms Driving Neuroendocrine Cancer Growth

Michael German, MD has been named a Petersen Investigator for his work to explore the use of an FDA approved inhibitor of Mek1/2 in preclinical models of neuroendocrine tumors. Dr. German, from the University of California at San Francisco, has been awarded a two-year, $300,000 grant for his project entitled “Treating Neuroendocrine Tumors Via Synthetic Lethality.”

Synthetic lethality is a concept in genetics between two genes where mutation of either alone is compatible with life but mutation of both leads to cell death. READ MORE

THE NEUROENDOCRINE TUMOR RESEARCH FOUNDATION PARTNERS WITH PATTERN .ORG TO ENABLE PATIENTS TO DIRECTLY CONTRIBUTE TISSUE SAMPLES TO RESEARCH PROJECTS

The Neuroendocrine Tumor Research Foundation is excited to be working with Pattern.org to empower patients to direct their excess cancer tissue samples to research projects. Initially, samples donated via Pattern.org will be sent to the Broad Institute of MIT and Harvard (www.broadinstitute.org), where they will be used to attempt to develop research models.

The Neuroendocrine Tumor Research Foundation’s partnership with Pattern.org and the Broad Institute is part of a larger effort to establish and genetically characterize cancer cell lines, which are cancer cells that keep dividing and growing over time, under certain conditions in a laboratory. In developing these cancer cell lines, the Broad Institute is trying to enable the scientific community to improve our understanding of cancer, including neuroendocrine tumors. READ MORE

THANK YOU FOR SUPPORTING NETRF IN 2016

Thanks to your support, the NET Research Foundation has been able to fund groundbreaking research. This year, with your help, we will be supporting projects with the potential to unlock our understanding of neuroendocrine cancers, including the Accelerator Research Grants Program – funding the best ideas and the best labs to drive progress forward at a faster pace. At the same time, we will continue to be a trusted resource for patient education and advocacy. We want to thank YOU, our community, for strengthening and advancing critical research to find a cure.

SIXTH ANNUAL BAY AREA NET PATIENT EDUCATION CONFERENCE
Saturday, February 4th, 2017

Hosted by the Stanford Cancer Center and the NET Research Foundation, in cooperation with UCSF Helen Diller Family Comprehensive Cancer Center and the NorCal CarciNET Community

The conference will be live streamed! If you cannot attend in person, join us online for the livestream.

We are pleased to bring together our extensive community of patients, loved ones, medical professionals, and supporters for the 2017 Bay Area Neuroendocrine Tumor Patient Education Conference.

Please join us to learn more about the latest developments in research and clinical care for patients with neuroendocrine cancers.

We are pleased to announce that this eUpdate
is sponsored by Novartis Pharmaceutical Corporation.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

20 Park Plaza, Suite 478
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.

Subscribe to our email list.